Both Targeted Mass Spectrometry and Flow Sorting Analysis Methods Detected the Decreased Serum Apolipoprotein E Level in Alzheimer's Disease Patients
Open accessAbstract
Apolipoprotein E (ApoE) polymorphism has been appreciated as a valuable predictor of Alzheimer disease (AD), and the associated ε4 allele has been recognized as an indicator of susceptibility to this disease. However, serum ApoE levels have been a controversial issue in AD, due to the great variability regarding the different target detection methods, ethnicity, and the geographic variations of cohorts. The aim of this study was to validate serum ApoE levels in relation to AD, particularly using two distinct detection methods, liquid chromatography-selected reaction monitoring (SRM) mass spectrometry and microsphere-based fluorescence-activated cell sorting (FACS) analysis, to overcome experimental variations. Also, comparison of serum ApoE levels was performed between the level of protein detection by FACS and peptide level by SRM in both control and AD patients. Results from the two detection methods were cross-confirmed and validated. Both methods produced fairly consistent results, showing a significant decrease of serum ApoE levels in AD patients relative to those of a control cohort (43 control versus 45 AD, p < 0.0001). Significant correlation has been revealed between results from FACS and SRM (p < 0.0001) even though lower serum ApoE concentration values were measured in protein by FACS analysis than in peptide-level detections by SRM. Correlation study suggested that a decrease of the serum ApoE level in AD is related to the mini-mental state exam score in both results from different experimental methods, but it failed to show consistent correlation with age, gender, or clinical dementia rating.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several studies have successfully used targeted MS strategies to quantify Aβ, tau, and APOE protein levels in CSF with similar disease-association efficacy to that of traditional ELISA assays.
“Several studies have successfully used targeted MS strategies to quantify Aβ, tau, and APOE protein levels in CSF with similar disease-association efficacy to that of traditional ELISA assays [189–191].”
From Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2021) · cites this paper as [191]
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · see citing works
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786 · see citing works
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · see citing works
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836 · see citing works
Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins
Anderson, L., & Hunter, C. L. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500331-mcp200 · Cited by 1,230 · see citing works
Apolipoprotein E Polymorphism and Cardiovascular Disease: A HuGE Review
Eichner, J. E. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.6.487 · Cited by 796 · see citing works
Mapping Scores Onto Stages: Mini-Mental State Examination and Clinical Dementia Rating
Perneczky, R., Wagenpfeil, S., Komossa, K., Grimmer, T., Diehl, J., & Kurz, A. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000192478.82189.a8 · Cited by 768 · see citing works
Rates and risk factors for dementia and Alzheimer’s disease: Results from EURODEM pooled analyses
Launer, L. J., Andersen, K., Dewey, M. E., Letenneur, L., Ott, A., Amaducci, L. A., Brayne, C., Copeland, J. R. M., Dartigues, J.-F., Kragh-Sorensen, P., et al. (1999) · Neurology · doi:10.1212/wnl.52.1.78 · Cited by 758 · see citing works
APOLIPOPROTEIN E ALLELES AS RISK FACTORS IN ALZHEIMER'S DISEASE
Roses, M. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.387 · Cited by 707 · see citing works
(1985) · PubMed · Cited by 706 · see citing works
Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J., Jackson, A. M., Hardie, D. B., Anderson, N. L., & Borchers, C. H. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800540-mcp200 · Cited by 515 · see citing works
Hallman, D. M., Boerwinkle, E., Saha, N., Sandholzer, C., Menzel, H., Csazar, A., & Utermann, G. (1991) · PubMed · Cited by 511 · see citing works
High-throughput generation of selected reaction-monitoring assays for proteins and proteomes
Picotti, P., Rinner, O., Stallmach, R., Dautel, F., Farrah, T., Domon, B., Wenschuh, H., & Aebersold, R. H. (2009) · Nature Methods · doi:10.1038/nmeth.1408 · Cited by 452 · see citing works
Isotope-labeled Protein Standards
Brun, V., Dupuis, A., Adrait, A., Marcellin, M., Thomas, D. Y., Court, M., Vandenesch, F., & Garin, J. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700163-mcp200 · Cited by 443 · see citing works
Olsson, A., Vanderstichele, H., Andreasen, N., Meyer, G. D., Wallin, A., Holmberg, B., Rosengren, L., Vanmechelen, E., & Blennow, K. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039347 · Cited by 424 · see citing works
Incidence of Dementia and Alzheimer Disease in 2 Communities
Hendrie, H. C., Ogunniyi, A. O., Hall, K. S., Baiyewu, O., Unverzagt, F. W., Gureje, O., Gao, S., Evans, R. M., Ogunseyinde, A. O., Adeyinka, A. O., et al. (2001) · JAMA · doi:10.1001/jama.285.6.739 · Cited by 393 · see citing works
Martins, I. J., Hone, E., Foster, J. K., Sünram-Lea, S. I., Gnjec, A., Fuller, S. J., Nolan, D., Gandy, S. E., & Martins, R. N. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001854 · Cited by 388 · see citing works
A targeted proteomics–based pipeline for verification of biomarkers in plasma
Whiteaker, J. R., Lin, C., Kennedy, J. J., Hou, L., Trute, M., Sokal, I., Yan, P., Schoenherr, R. M., Zhao, L., Voytovich, U. J., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1900 · Cited by 365 · see citing works
Proc, J. L., Kuzyk, M. A., Hardie, D. B., Yang, J., SMITH, D. S. H., Jackson, A., Parker, C. E., & Borchers, C. H. (2010) · Journal of Proteome Research · doi:10.1021/pr100656u · Cited by 354 · see citing works
Apolipoprotein E: an important gene and protein to follow in laboratory medicine
Siest, G., Pillot, T., Régis-Bailly, A., Leininger-Muller, B., Steinmetz, J., Galteau, M. M., & Visvikis, S. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.8.1068 · Cited by 347 · see citing works
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 291 · see citing works
Apolipoprotein E: risk factor for Alzheimer disease.
Tsai, M. S., Tangalos, E. G., Petersen, R. C., Smith, G. E., Schaid, D. J., Kokmen, E., Ivnik, R. J., & Thibodeau, S. N. (1994) · PubMed Central · Cited by 265 · see citing works
Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene
Artiga, M. J., Bullido, M. J., Sastre, I., Recuero, M., Garcı́a, M. A., Aldudo, J., Vázquez, J., & Valdivieso, F. (1998) · FEBS Letters · doi:10.1016/s0014-5793(97)01543-3 · Cited by 229 · see citing works
Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP™ assay
Prabhakar, U., Eirikis, E., & Davis, H. M. (2002) · Journal of Immunological Methods · doi:10.1016/s0022-1759(01)00543-9 · Cited by 185 · see citing works
A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease
Lambert, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.3.533 · Cited by 184 · see citing works
Fortin, T., Salvador, A., Charrier, J., Lenz, C., Lacoux, X., Morla, A., Choquet‐Kastylevsky, G., & Lemoine, J. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800238-mcp200 · Cited by 177 · see citing works
Perspectives of targeted mass spectrometry for protein biomarker verification
Hüttenhain, R., Malmström, J. A., Picotti, P., & Aebersold, R. H. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.09.014 · Cited by 173 · see citing works
Brain network local interconnectivity loss in aging APOE -4 allele carriers
Brown, J. A., Terashima, K. H., Burggren, A. C., Ercoli, L. M., Miller, K. J., Small, G. W., & Bookheimer, S. Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109038108 · Cited by 167 · see citing works
The Alzheimer's disease assessment scale
Doraiswamy, P. M., Bieber, F., Kaiser, L., Krishnan, K. R. R., Reuning-Scherer, J. D., & Gulanski, B. (1997) · Neurology · doi:10.1212/wnl.48.6.1511 · Cited by 166 · see citing works
Lack of an association between apolipoprotein E ϵ4 and Alzheimer's disease in elderly nigerians
Osuntokun, B. O., Sahota, A. S., Ogunniyi, A. O., Gureje, O., Baiyewu, O., Adeyinka, A. O., Oluwole, S., Komolafe, O. O., Hall, K. S., Unverzagt, F. W., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380319 · Cited by 158 · see citing works
Accurate Inclusion Mass Screening
Jaffe, J. D., Keshishian, H., Chang, B., Addona, T. A., Gillette, M. A., & Carr, S. A. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800218-mcp200 · Cited by 154 · see citing works
Plasma apolipoprotein E and Alzheimer disease risk: The AIBL study of aging
Gupta, V. B., Laws, S. M., Villemagne, V. L., Ames, D., Bush, A. I., Ellis, K. A., Lui, J. K., Masters, C., Rowe, C. C., Szoeke, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318211c352 · Cited by 149 · see citing works
Schiele, F., Bacquer, D. D., Vincent‐Viry, M., Beisiegel†, U., Ehnholm, C., Evans, A., Kafatos, A., Martins, M. C., Sans, S., Sass, C., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00501-8 · Cited by 143 · see citing works
Multiplexed Analysis of Human Cytokines by Use of the FlowMetrix System
Oliver, K. G., Kettman, J. R., & Fulton, R. J. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.9.2057 · Cited by 140 · see citing works
Lehtim�ki, T., Pirttil�, T., Mehta, P., Wisniewski, H., Frey, H., & Nikkari, T. (1995) · Human Genetics · doi:10.1007/bf00225071 · Cited by 125 · see citing works
Ueki, A., Kawano, M., Namba, Y., Kawakami, M., & Ikeda, K. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90373-s · Cited by 114 · see citing works
Martins, R. N., Clarnette, R., Fisher, C., Broe, G. A., Brooks, W. S., Montgomery, P., & Gandy, S. (1995) · Neuroreport · doi:10.1097/00001756-199507310-00012 · Cited by 105 · see citing works
Mirzaei, H., McBee, J. K., Watts, J. D., & Aebersold, R. H. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m700495-mcp200 · Cited by 98 · see citing works
Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease
Taddei, K., Clarnette, R., Gandy, S., & Martins, R. N. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13394-8 · Cited by 98 · see citing works
Pan, S., Chen, R., Brand, R. E., Hawley, S. J., Tamura, Y., Gafken, P. R., Milless, B. P., Goodlett, D. R., Rush, A. J., & Brentnall, T. A. (2012) · Journal of Proteome Research · doi:10.1021/pr201117w · Cited by 96 · see citing works
Haddy, N., Bacquer, D. D., Chemaly, M. M., Maurice, M., Ehnholm, C., Evans, A., Sans, S., Martins, M. D. C., Backer, G. D., Siest, G., et al. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200864 · Cited by 92 · see citing works
Simon, R., Girod, M., Fonbonne, C., Salvador, A., Clément, Y., Lantéri, P., Amouyel, P., Lambert, J. C., & Lemoine, J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.018861 · Cited by 92 · see citing works
Juva, K., Sulkava, R., Erkinjuntti, T., Ylikoski, R., Valvanne, J., & Tilvis, R. (1994) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb02724.x · Cited by 87 · see citing works
Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease
Scacchi, R., Gambina, G., Ruggeri, M., Martini, M. C., Ferrari, G., Silvestri, M., Schiavon, R., & Corbo, R. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00889-1 · Cited by 83 · see citing works
Alzheimer’s drugs take a new tack
Callaway, E. (2012) · Nature · doi:10.1038/489013a · Cited by 77 · see citing works
Siest, G., Bertrand, P., Qin, B. Y., Herbeth, B., Sérot, J., Masana, L., Ribalta, J., Passmore, A. P., Evans, A., Ferrari, M., et al. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.102 · Cited by 74 · see citing works
Vincent‐Viry, M., Schiele, F., Gueguen, R., Bohnet, K., Visvikis‐Siest, S., & Siest, G. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.5.957 · Cited by 73 · see citing works
Mui, S., Briggs, M. E., Chung, H., Wallace, R. B., Gómez‐Isla, T., Rebeck, G. W., & Hyman, B. T. (1996) · Neurology · doi:10.1212/wnl.47.1.196 · Cited by 68 · see citing works
Fukumoto, H., Ingelsson, M., Gårevik, N., Wahlund, L.-O., Nukina, N., Yaguchi, Y., Shibata, M., Hyman, B. T., Rebeck, G. W., & Irizarry, M. C. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00088-8 · Cited by 63 · see citing works
Apolipoprotein E and Alzheimer's Disease: A Review of Recent Studies
Higgins, G. A., Large, C. H., Rupniak, H. T., & Barnes, J. C. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00420-0 · Cited by 60 · see citing works
Alzheimer's disease: a review of the disease, its epidemiology and economic impact
Alloul, K., Sauriol, L., Kennedy, W. A., Laurier, C., Tessier, G., Novosel, S., & Contandriopoulos, A. (1998) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(98)00116-2 · Cited by 58 · see citing works
Multiplexed quantification of human IgG, IgA, and IgM with the FlowMetrix system.
Gordon, R. F., & McDade, R. L. (1997) · PubMed · Cited by 54 · see citing works
Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study
Slooter, A. J. C., de Knijff, P., Albert Hofman, D., Cruts, M., Breteler, M. M. B., Broeckhoven, C. V., Havekes, L. M., & van Duijn, C. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00339-5 · Cited by 54 · see citing works
Correlation between y-Type Ions Observed in Ion Trap and Triple Quadrupole Mass Spectrometers
Sherwood, C. A., Eastham, A., Lee, L. W., Risler, J., Olga Vitek, A., & Martin, D. B. (2009) · Journal of Proteome Research · doi:10.1021/pr900298b · Cited by 53 · see citing works
Panza, F., Solfrizzi, V., Colacicco, A. M., Basile, A. M., D’Introno, A., Capurso, C. A., Sabba, M., Capurso, S. A., & Capurso, A. (2003) · Neuroreport · doi:10.1097/00001756-200303240-00016 · Cited by 50 · see citing works
Berglund, L., Wiklund, O., Eggertsen, G., Olofsson, S. ‐., Eriksson, M., LINDÉN, T., Bondjers, G., & Angelin, B. (1993) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1993.tb00670.x · Cited by 49 · see citing works
Multiplexed Quantification of Human IgG, IgA, and IgM with the FlowMetrixTM System,
Gordon, R. F., & McDade, R. L. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.9.1799 · Cited by 48 · see citing works
Kim, H., Kim, D.-K., Choi, I.-J., Kang, K. H., Yi, S., Park, J., & Park, Y. (2001) · Psychiatry and Clinical Neurosciences · doi:10.1046/j.1440-1819.2001.00797.x · Cited by 27 · see citing works
APOE ε4 Allele Status in Korean Dementia Patients with Severe White Matter Hyperintensities
Hong, Y. J., Yoon, B., Shim, Y. S., Cho, A.-H., Shin, H., Kim, Y.-I., Kim, S., & Yang, D. W. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-101611 · Cited by 25 · see citing works
Perspective: In search of biomarkers
Buckholtz, N. S. (2011) · Nature · doi:10.1038/475s8a · Cited by 24 · see citing works
Rajcan‐Separovic, E., Wang, H., Speevak, M. D., et al. (1995) · Human Genetics · doi:10.1007/bf00214184 · Cited by 19 · see citing works
Sachdev (1999) · doi:10.1002/(sici)1099-1166(199905)14:5
Flagged first, then by citations
Cited by
Sorted by citations
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
Rayaprolu, S., Higginbotham, L., Bagchi, P., Watson, C. M., Zhang, T., Levey, A. I., Rangaraju, S., & Seyfried, N. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00840-3 · Cited by 118 · see citing works
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67 · see citing works
Self-citationCilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60 · see citing works
- Authors
- Han, S.-H., Kim, J. S., Lee, Y., Choi, H., Kim, J.-W., Na, D. L., Yang, E. G., Yu, M.-H., Hwang, D., Lee, C., & Mook-Jung, I.
- Affiliations
- Seoul National University (KR)
- Samsung Medical Center (KR)
- Korea Institute of Science and Technology (KR)
- Pohang University of Science and Technology (KR)
- Corresponding author
- Lee, Cheolju
- Venue
- Molecular & Cellular Proteomics
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 13
- Issue
- 2
- Pages
- 407-419
- ISSN
- 1535-9476 (ISSN-L)
- PMC
- PMC3916643
- OpenAlex
- W2108818213
- Cited by
- 29
- References
- 66
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 3 · 2016: 4 · 2015: 6 · 2014: 1
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular & Cellular Proteomics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Keywords
- apolipoprotein E, Alzheimer's disease, APOE polymorphism, APOE ε4, fluorescence-activated cell sorting, method validation, Mini-Mental State Examination, biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Apolipoproteins E, Blood Chemical Analysis, Female, Flow Cytometry, Humans, Male, Microspheres, Middle Aged, Molecular Sequence Data, Mass Spectrometry, Reproducibility of Results, Down-Regulation, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
